Cargando…

Characterization of Dosage Levels for In Ovo Administration of Innate Immune Stimulants for Prevention of Yolk Sac Infection in Chicks

Innate immune stimulants, especially toll-like receptor (TLR) ligands and agonists, are the main players in the initiation of innate immunity and have been widely studied as alternatives to antibiotics to control infection. In the present study, we characterized the dosage levels of various innate i...

Descripción completa

Detalles Bibliográficos
Autores principales: Sarfraz, Mishal, Nguyen, Thuy Thi Thu, Wheler, Colette, Köster, Wolfgang, Gerdts, Volker, Dar, Arshud
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9142911/
https://www.ncbi.nlm.nih.gov/pubmed/35622731
http://dx.doi.org/10.3390/vetsci9050203
_version_ 1784715676172156928
author Sarfraz, Mishal
Nguyen, Thuy Thi Thu
Wheler, Colette
Köster, Wolfgang
Gerdts, Volker
Dar, Arshud
author_facet Sarfraz, Mishal
Nguyen, Thuy Thi Thu
Wheler, Colette
Köster, Wolfgang
Gerdts, Volker
Dar, Arshud
author_sort Sarfraz, Mishal
collection PubMed
description Innate immune stimulants, especially toll-like receptor (TLR) ligands and agonists, are the main players in the initiation of innate immunity and have been widely studied as alternatives to antibiotics to control infection. In the present study, we characterized the dosage levels of various innate immune stimulants, including unmethylated cytosine-phosphate-guanosine dinucleotide -containing oligodeoxynucleotides (CpG ODN), polyinosinic-polycytidylic acid (poly I:C), cyclic polyphosphazene 75B (CPZ75B), avian beta-defensin 2 (ABD2), and combinations of these reagents given in ovo. Data derived from a series of animal experiments demonstrated that the in ovo administration of 10–50 µg CpG ODN/embryo (on embryonic day 18) is an effective formulation for control of yolk sac infection (YSI) due to avian pathogenic Escherichia coli (E. coli) in young chicks. Amongst the different combinations of innate immune stimulants, the in ovo administration of CpG ODN 10 µg in combination with 15 µg of poly I:C was the most effective combination, offering 100% protection from YSI. It is expected that the introduction of these reagents to management practices at the hatchery level may serve as a potential replacement for antibiotics for the reduction of early chick mortality (ECM) due to YSI/colibacillosis.
format Online
Article
Text
id pubmed-9142911
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-91429112022-05-29 Characterization of Dosage Levels for In Ovo Administration of Innate Immune Stimulants for Prevention of Yolk Sac Infection in Chicks Sarfraz, Mishal Nguyen, Thuy Thi Thu Wheler, Colette Köster, Wolfgang Gerdts, Volker Dar, Arshud Vet Sci Article Innate immune stimulants, especially toll-like receptor (TLR) ligands and agonists, are the main players in the initiation of innate immunity and have been widely studied as alternatives to antibiotics to control infection. In the present study, we characterized the dosage levels of various innate immune stimulants, including unmethylated cytosine-phosphate-guanosine dinucleotide -containing oligodeoxynucleotides (CpG ODN), polyinosinic-polycytidylic acid (poly I:C), cyclic polyphosphazene 75B (CPZ75B), avian beta-defensin 2 (ABD2), and combinations of these reagents given in ovo. Data derived from a series of animal experiments demonstrated that the in ovo administration of 10–50 µg CpG ODN/embryo (on embryonic day 18) is an effective formulation for control of yolk sac infection (YSI) due to avian pathogenic Escherichia coli (E. coli) in young chicks. Amongst the different combinations of innate immune stimulants, the in ovo administration of CpG ODN 10 µg in combination with 15 µg of poly I:C was the most effective combination, offering 100% protection from YSI. It is expected that the introduction of these reagents to management practices at the hatchery level may serve as a potential replacement for antibiotics for the reduction of early chick mortality (ECM) due to YSI/colibacillosis. MDPI 2022-04-22 /pmc/articles/PMC9142911/ /pubmed/35622731 http://dx.doi.org/10.3390/vetsci9050203 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Sarfraz, Mishal
Nguyen, Thuy Thi Thu
Wheler, Colette
Köster, Wolfgang
Gerdts, Volker
Dar, Arshud
Characterization of Dosage Levels for In Ovo Administration of Innate Immune Stimulants for Prevention of Yolk Sac Infection in Chicks
title Characterization of Dosage Levels for In Ovo Administration of Innate Immune Stimulants for Prevention of Yolk Sac Infection in Chicks
title_full Characterization of Dosage Levels for In Ovo Administration of Innate Immune Stimulants for Prevention of Yolk Sac Infection in Chicks
title_fullStr Characterization of Dosage Levels for In Ovo Administration of Innate Immune Stimulants for Prevention of Yolk Sac Infection in Chicks
title_full_unstemmed Characterization of Dosage Levels for In Ovo Administration of Innate Immune Stimulants for Prevention of Yolk Sac Infection in Chicks
title_short Characterization of Dosage Levels for In Ovo Administration of Innate Immune Stimulants for Prevention of Yolk Sac Infection in Chicks
title_sort characterization of dosage levels for in ovo administration of innate immune stimulants for prevention of yolk sac infection in chicks
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9142911/
https://www.ncbi.nlm.nih.gov/pubmed/35622731
http://dx.doi.org/10.3390/vetsci9050203
work_keys_str_mv AT sarfrazmishal characterizationofdosagelevelsforinovoadministrationofinnateimmunestimulantsforpreventionofyolksacinfectioninchicks
AT nguyenthuythithu characterizationofdosagelevelsforinovoadministrationofinnateimmunestimulantsforpreventionofyolksacinfectioninchicks
AT whelercolette characterizationofdosagelevelsforinovoadministrationofinnateimmunestimulantsforpreventionofyolksacinfectioninchicks
AT kosterwolfgang characterizationofdosagelevelsforinovoadministrationofinnateimmunestimulantsforpreventionofyolksacinfectioninchicks
AT gerdtsvolker characterizationofdosagelevelsforinovoadministrationofinnateimmunestimulantsforpreventionofyolksacinfectioninchicks
AT dararshud characterizationofdosagelevelsforinovoadministrationofinnateimmunestimulantsforpreventionofyolksacinfectioninchicks